|  |
| --- |
| **Supplementary Table 1:** PAS biomarkers candidates in maternal circulation. |
| Type | Biomarker | Study | Aim | Trimester | Total cases | Trends in PAS | AUC |
| Peptides and proteins | AFP | Dreux et al.[1], 2012; Lyell et al.[2], 2015; Oztas et al.[3], 2016\*; Pekar-Zlotin et al.[4], 2018; Berezowsky et al.[5], 2019 | PAS diagnosis/(hysterectomy or not) | First/second | 621†/736†/316†/76/301 | ↑ | -/-/0.742/-/0.573 |
| PAPP-A | Desai et al.[6], 2014\*; Lyell et al.[2], 2015; Büke et al.[7], 2018; Penzhoyan et al.[8], 2019\* | PAS diagnosis | First/Second | 82/736†/88/87 | ↑ | - |
| β-hCG | Dreux et al.[9], 2012; Desai et al.[6], 2014\*; Büke et al.[7], 2018; Berezowsky et al.[10], 2019, Pekar-Zlotin et al.[11], 2018; | PAS diagnosis | First/Second | 621†/82/88/301†/76 | ↑/↓ | -/-/-/0.662/- |
| H-hCG | Einerson et al.[12], 2019\*; Al-Khan et al.[13], 2020\* | PAS diagnosis | Second/Third | 60/88 | ↓, - | 0.68/- |
| IMA, Thiol | Uyanikoglu et al.[14], 2018\* | PAS subtypes | Third | 78 | ↑, ↓ | - |
| CK, CK-MB | Ersoy et al.[15], 2016\* | PAS diagnosis | Pre-operation | 100 | -, - | -/- |
| Troponin Ⅰ | Ersoy et al.[15], 2016\* | PAS diagnosis | Pre-operation | 100 | ↑ | 0.808 |
| ProBNP | Ersoy et al.[15], 2016\* | PAS diagnosis | Pre-operation | 100 | ↑ | 0.831 |
| IL-8, Decorin | Al-Khan et al.[13], 2020\* | PAS diagnosis | Second/Third | 88 | -, ↑ | - |
| TRAIL-R2 | Oztas et al.[16], 2016\* | PAS diagnosis | Pre-operation | 82 | ↓ | - |
| Vascular endothelial factors | VEGF, PIGF, sFlt-1 | Wehrum et al.[17], 2011\*; Biberoglu et al.[18], 2016; Uyanıkoğlu et al.[19], 2018\*; Schwickert, et al.[20], 2021 | PAS diagnosis/PAS subtypes | Third/ Pre-operation | 90/98/44/99 | ↓, ↓, ↓ | -/-/-/0.729 (0.915‡) |
| VEGFR2, sTie2, PAI-1, ATⅢ | Shainker et al.[21], 2020 | PAS diagnosis | Third | 26 | ↑, ↑, ↓, ↑ | - |
| DNA | cffDNA | Samuel et al.[22], 2013 | PAS diagnosis | Third | 20 | - | - |
| RNA | cffRNA, | El Behery et al.[23], 2010\* | PAS diagnosis/PAS subtypes | Third | 35 | ↑ | - |
| cffRNA(β-hCG) | Zhou et al.[24], 2014 | PAS diagnosis | Third | 68 | ↑ | - |
| cffRNA (hPL) | Kawashima et al.[25], 2014\*; Li et al.[26], 2019 | PAS diagnosis | Third | 110/68 | ↑ | 0.97/- |
| miRNA (miR‐490-3p, miR-133a-3p) | Yang et al.[27], 2020\* | Operation-related blood volume loss | Pre-operation | 20 | ↑ | - |
| miR-139-3p | Chen et al.[28], 2020 | PAS diagnosis | Third | 186 | ↓ | 0.73 |
| miR-196a-5p | Chen et al.[28], 2020 | PAS diagnosis | Third | 186 | ↓ | 0.74 |
| miR-518a-3p | Chen et al.[28], 2020 | PAS diagnosis | Third | 186 | ↓ | 0.59 |
| miR-671-3p | Chen et al.[28], 2020 | PAS diagnosis | Third | 186 | ↓ | 0.70 (0.91‡) |
| Cells | cTBs | Afshar et al.[29], 2021\* | PAS diagnosis | First/Second/Third | 168 | ↑ | 0.942 (0.976‡) |
| ATⅢ: antithrombinⅢ; AFP: alpha-fetoprotein; β-hCG: beta- human chorionic gonadotropin; BNP: ProBNP: Pro-brain natriuretic peptide; cffDNA: cell-free fetal DNA; cffRNA: cell-free fetal RNA; cTBs: circulating trophoblasts; CK: creatine kinase; CK-MB: creatine kinase-MB; H-hCG: hyperglycosylated human chorionic gonadotropin; HPL: human placental lactogen; IL-8: interleukin-8; IMA: ischemia modified albumin; miRNA: MicroRNA; PAI-1: plasminogen activator inhibitor 1; PAPP-A: pregnancy associated plasma protein A; PAS: placenta accreta spectrum; PIGF: placenta growth factor; sFlt-1: soluble Fms-like tyrosine kinase 1; VEGF: vascular endothelial growth factor; VEGFR2: vascular endothelial growth factor receptor 2; TRAIL-R2: tumor necrosis factor related apoptosis-inducing ligand receptor 2. \*All PAS cases confirmed by the histopathologic confirmation only. †The large cohort was from the prenatal screening program. ‡Single biomarker combined with other index including other biomarkers, clinical risk factors or imaging findings. |

**References**

1. Dreux S, Salomon LJ, Muller F, Goffinet F, Oury J-F, Sentilhes L. Second-trimester maternal serum markers and placenta accreta. Prenat Diagn2012;32:1010-1012. doi: 10.1002/pd.3932.

2. Lyell DJ, Faucett AM, Baer RJ, Blumenfeld YJ, Druzin ML, El-Sayed YY*, et al.* Maternal serum markers, characteristics and morbidly adherent placenta in women with previa. Journal of perinatology : official journal of the California Perinatal Association2015;35:570-574. doi: 10.1038/jp.2015.40.

3. Oztas E, Ozler S, Caglar AT, Yucel A. Analysis of first and second trimester maternal serum analytes for the prediction of morbidly adherent placenta requiring hysterectomy. The Kaohsiung journal of medical sciences2016;32:579-585. doi: 10.1016/j.kjms.2016.08.011.

4. Pekar-Zlotin M, Melcer Y, Maymon R, Jauniaux E. Second-trimester levels of fetoplacental hormones among women with placenta accreta spectrum disorders. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2018;140:377-378. doi: 10.1002/ijgo.12352.

5. Berezowsky A, Pardo J, Ben-Zion M, Wiznitzer A, Aviram A. Second Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study. Fetal Diagn Ther2019;46:187-192. doi: 10.1159/000492829.

6. Desai N, Krantz D, Roman A, Fleischer A, Boulis S, Rochelson B. Elevated first trimester PAPP--a is associated with increased risk of placenta accreta. Prenat Diagn2014;34:159-162. doi: 10.1002/pd.4277.

7. Büke B, Akkaya H, Demir S, Sağol S, Şimşek D, Başol G*, et al.* Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians2018;31:59-62. doi: 10.1080/14767058.2016.1275546.

8. Penzhoyan GA, Makukhina TB. Significance of the routine first-trimester antenatal screening program for aneuploidy in the assessment of the risk of placenta accreta spectrum disorders. J Perinat Med2019;48:21-26. doi: 10.1515/jpm-2019-0261.

9. Dreux S, Salomon LJ, Muller F, Goffinet F, Oury JF, Sentilhes L. Second-trimester maternal serum markers and placenta accreta. Prenat Diagn2012;32:1010-1012. doi: 10.1002/pd.3932.

10. Berezowsky A, Pardo J, Ben-Zion M, Wiznitzer A, Aviram A. Second Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study. Fetal Diagn Ther2019;46:187-192. doi: 10.1159/000492829.

11. Marina P-Z, Yaakov M, Ron M, Eric J. Second-trimester levels of fetoplacental hormones among women with placenta accreta spectrum disorders. %J International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2018;140. doi.

12. Einerson BD, Straubhar A, Soisson S, Szczotka K, Dodson MK, Silver RM*, et al.* Hyperglycosylated hCG and Placenta Accreta Spectrum. Am J Perinatol2019;36:22-26. doi: 10.1055/s-0038-1636501.

13. Al-Khan A, Youssef YH, Feldman KM, Illsley NP, Remache Y, Alvarez-Perez J*, et al.* Biomarkers of abnormally invasive placenta. Placenta2020;91:37-42. doi: 10.1016/j.placenta.2020.01.007.

14. Uyanikoglu H, Sak ME, Tatli F, Hilali NG, Sak S, Incebiyik A*, et al.* Serum ischemia modified albumin level and its relationship with the thiol/disulfide balance in placenta percreta patients. J Obstet Gynaecol2018;38:1073-1077. doi: 10.1080/01443615.2018.1450369.

15. Ersoy AO, Oztas E, Ozler S, Ersoy E, Erkenekli K, Uygur D*, et al.* Can venous ProBNP levels predict placenta accreta? The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians2016;29:4020-4024. doi: 10.3109/14767058.2016.1152576.

16. Oztas E, Ozler S, Ersoy AO, Ersoy E, Caglar AT, Uygur D*, et al.* Decreased placental and maternal serum TRAIL-R2 levels are associated with placenta accreta. Placenta2016;39:1-6. doi: 10.1016/j.placenta.2016.01.004.

17. Wehrum MJ, Buhimschi IA, Salafia C, Thung S, Bahtiyar MO, Werner EF*, et al.* Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast. Am J Obstet Gynecol2011;204. doi: 10.1016/j.ajog.2010.12.027.

18. Biberoglu E, Kirbas A, Daglar K, Biberoglu K, Timur H, Demirtas C*, et al.* Serum angiogenic profile in abnormal placentation. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians2016;29:3193-3197. doi: 10.3109/14767058.2015.1118044.

19. Uyanıkoğlu H, İncebıyık A, Turp AB, Çakmak G, Sak S, Hilali NG. Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta. Balkan medical journal2018;35:55-60. doi: 10.4274/balkanmedj.2016.1890.

20. Schwickert A, Chantraine F, Ehrlich L, Henrich W, Muallem MZ, Nonnenmacher A*, et al.* Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study. Reprod Sci2021;28:361-370. doi: 10.1007/s43032-020-00319-y.

21. Shainker SA, Silver RM, Modest AM, Hacker MR, Hecht JL, Salahuddin S*, et al.* Placenta accreta spectrum: biomarker discovery using plasma proteomics. Am J Obstet Gynecol2020;223. doi: 10.1016/j.ajog.2020.03.019.

22. Samuel A, Bonanno C, Oliphant A, Batey A, Wright JD. Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion-a pilot study. Prenat Diagn2013;33:1050-1053. doi: 10.1002/pd.4195.

23. El Behery MM, Rasha L E, El Alfy Y. Cell-free placental mRNA in maternal plasma to predict placental invasion in patients with placenta accreta. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2010;109:30-33. doi: 10.1016/j.ijgo.2009.11.013.

24. Zhou J, Li J, Yan P, Ye YH, Peng W, Wang S*, et al.* Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete. Placenta2014;35:691-695. doi: 10.1016/j.placenta.2014.07.007.

25. Kawashima A, Sekizawa A, Ventura W, Koide K, Hori K, Okai T*, et al.* Increased levels of cell-free human placental lactogen mRNA at 28-32 gestational weeks in plasma of pregnant women with placenta previa and invasive placenta. Reproductive sciences (Thousand Oaks, Calif)2014;21:215-220. doi: 10.1177/1933719113492209.

26. Li J, Zhang N, Zhang Y, Hu X, Gao G, Ye Y*, et al.* Human placental lactogen mRNA in maternal plasma play a role in prenatal diagnosis of abnormally invasive placenta: yes or no? Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology2019;35:631-634. doi: 10.1080/09513590.2019.1576607.

27. Yang T, Li N, Hou R, Qiao C, Liu C. Development and validation of a four-microRNA signature for placenta accreta spectrum: an integrated competing endogenous RNA network analysis. Annals of translational medicine2020;8:919. doi: 10.21037/atm-20-1150.

28. Chen S, Pang D, Li Y, Zhou J, Liu Y, Yang S*, et al.* Serum miRNA biomarker discovery for placenta accreta spectrum. Placenta2020;101:215-220. doi: 10.1016/j.placenta.2020.09.068.

29. Afshar Y, Dong J, Zhao P, Li L, Wang S, Zhang RY*, et al.* Circulating trophoblast cell clusters for early detection of placenta accreta spectrum disorders. Nature communications2021;12:4408. doi: 10.1038/s41467-021-24627-2.